Trial Profile
A Phase III, Double-Blind, Placebo Controlled Trial of Gemcitabine Plus Placebo Versus Gemcitabine Plus R115777 [tipifarnib] in Patients With Advanced Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2019
Price :
$35
*
At a glance
- Drugs Tipifarnib (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 19 Jan 2019 Results of a retrospective analysis assessing patient reported abdominal pain as a surrogate of the clinical benefit of tipifarnib in pancreatic cancer patients, presented at the 2019 Gastrointestinal Cancers Symposium
- 18 Jan 2019 Results of retrospective analysis, presented in a Kura Oncology media release.
- 26 Sep 2005 New trial record.